Epileptiform Activity During REM Sleep in Alzheimer's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

62 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-04-29

Study Completion Date

2023-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Recent clinical data showed that patients with Alzheimer Disease (AD) might present epilepsy at early stages of the disease (Cretin et al., 2016, Vossel et al., 2016). In mice models of Alzheimer disease, preclinical researchers observed an increase of epileptic events during Rapid Eye Movement (REM) sleep, which is very unusual. This study aims at testing if patients with AD present an exacerbation of epileptic events during REM sleep, which could constitute an early biomarker of the disease. Investigators will evaluate the incidence of epilepsy during each sleep stage in 40 patients with early or moderate forms of AD and in 40 healthy subjects. Investigators will also look for a link between epilepsy during sleep in AD participants and memory performances, brain damage (by using MRI scans) and in the case of patients, the phenotype of the Apolipoprotein E(ApoE) gene.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cartography of Functional and Epileptic Cerebral Areas by Functional MRI and Electroencephalography in Epileptic Patients Before and After Surgery

NCT03102957

Epilepsy

COMPLETED NA

Imaging of New Learning in Severe Alzheimer's Disease Patients

NCT01839422

Alzheimer Disease

UNKNOWN NA

Microstructural and Sodium 7 Tesla Brain MRI in Idiopathic REM Sleep Behaviour Disorder

NCT05976971

REM Sleep Behaviour Disorder

COMPLETED NA

Episodic Memory Before and After Surgery in Drug-resistant Partial Epilepsies

NCT01919957

Epilepsy, Unspecified, Pharmacologically Resistant Memory Impairment

UNKNOWN NA

Functional Magnetic Resonance Imaging - Synthetic Aperture Magnetometry (fMRI-SAM) and Alzheimer's Disease

NCT00412048

Alzheimer's Disease

WITHDRAWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Preclinical researchers discovered that the Tg2576 mouse model of Alzheimer Disease (AD) presents epileptiform activity specifically during sleep, with a prominent increase during REM-sleep. This phenotype is specific to AD mice since REM-sleep usually prevents seizures and epileptiform activity in animal models of epilepsy. Preclinical research also evidenced that this epileptic phenotype occurs at very early age in Tg2576 mice, far before the onset of cognitive impairments. Thus, it was hypothesized that patients with AD might present subclinical epileptiform events during sleep with a potential worsening during REM-sleep. If so, it could be used as a specific and early biomarker of AD. Since sleep is involved in memory consolidation processes, preclinical researchers also hypothesized that epileptiform events during sleep might participate to cognitive dysfunction in AD patients.

In order to test this hypothesis, a monocentric clinical study with a protocol consisting of three visits was designed aiming at evaluating seizures and subclinical epileptiform activity - and their consequences on memory - during sleep in 31 patients at early to moderate stages of AD and 31 matched healthy participants. During the first visit, a blood sample is collected of each patient for genetic testing of the ApoE gene before they undergo a high-resolution MRI scan. During the second visit (in the 60 days following the first one) participants first undergo a neuropsychological evaluation including visual, verbal and episodic memory tests before an overnight polysomnography. Following the overnight polysomnography, all subjects (patients and healthy participants) will be tested for the memories acquired the day before in order to evaluate sleep related memory consolidation. During the last visit, participants will fill out questionnaires aiming at evaluating pre-diagnostic lifestyle and they (and one family member if possible) will be interviewed about the presence of symptoms that might indicate an underlying epileptic syndrome for the participant. Healthy subjects will undergo the same procedures except for the blood test from which they will be exempted.

This should allow to evidence sleep related epileptic events, to precise their incidence in AD patients as well as in healthy participants, and to correlate these events to anomalies in brain structure and functional resting state connectivity (MRI) and/or sleep disturbances and/or cognitive decline.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer Disease, Early Onset

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

2 compared groups (Alzheimer's Disease patients vs controls)

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Alzheimer's Disease patients group

This group contains the 31 (anticipated) participants with a diagnosis of Alzheimer's disease

Group Type OTHER

Overnight polysomnography

Intervention Type DIAGNOSTIC_TEST

Overnight polysomnography with evaluation of each form of epileptiform activity during each vigilance state and memory scores at the overnight retention test

blood sample

Intervention Type DIAGNOSTIC_TEST

blood sample for genetic testing of the Apolipoprotein E

high-resolution MRI scan

Intervention Type DIAGNOSTIC_TEST

Evaluation of anomalies in brain structure and functional resting state connectivity

neuropsychological evaluation

Intervention Type BEHAVIORAL

neuropsychological evaluation including episodic memory tests before an overnight polysomnography

Healthy control group

This group contains the 31 (anticipated) age and sex -matched healthy controls

Group Type OTHER

Overnight polysomnography

Intervention Type DIAGNOSTIC_TEST

Overnight polysomnography with evaluation of each form of epileptiform activity during each vigilance state and memory scores at the overnight retention test

high-resolution MRI scan

Intervention Type DIAGNOSTIC_TEST

Evaluation of anomalies in brain structure and functional resting state connectivity

neuropsychological evaluation

Intervention Type BEHAVIORAL

neuropsychological evaluation including episodic memory tests before an overnight polysomnography

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Overnight polysomnography

Overnight polysomnography with evaluation of each form of epileptiform activity during each vigilance state and memory scores at the overnight retention test

Intervention Type DIAGNOSTIC_TEST

blood sample

blood sample for genetic testing of the Apolipoprotein E

Intervention Type DIAGNOSTIC_TEST

high-resolution MRI scan

Evaluation of anomalies in brain structure and functional resting state connectivity

Intervention Type DIAGNOSTIC_TEST

neuropsychological evaluation

neuropsychological evaluation including episodic memory tests before an overnight polysomnography

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

For all participants:

* age from 50 to 90 years old
* affiliated to the French health care system

For AD patients:

* meeting International Working Group (IWG)-2 criteria for diagnosis
* Mini-Mental State Examination (MMSE) ≥18 (Greco version)

For healthy volunteers:

* MMSE\>25
* Dubois 5 words test ≥ 9

Exclusion Criteria

For all participants:

* Pregnancy
* people not able to give consent
* contraindication for MRI (metallic body parts, claustrophobia),
* aphasia, apraxia or agnosia
* neurological (other than AD) or any other serious disease (cancer, addiction, systemic disease)
* non treated sleep apnea
* major depression or anxiety for more than 3 months (Beck\>10) or psychiatric disease
* documented epilepsy
* use of neuroleptics (more than one dose per day)
* use of antiepileptics
* use of benzodiazepines at a dose superior or equal to two intakes per day
* use of antidepressants
* restless leg syndrome treated by dopaminergic agonists.

For AD patients:

* other causes of dementia
* non-degenerative neurological lesions
* white matter hypersignals
* acute cognitive deficits

Minimum Eligible Age

50 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes